Psoralen
Psoralen has been studied in 4 papers since 2026: none in people yet, 2 in animals, 2 reviews; 4 in the past year. The research so far is in animals.
1 new paper in 30 daysSee all 4 papers on psoralen
At a glance
The findings reach mice, none yet in people. 2 independent labs in 1 country; 2 trials, none about aging, 1 with no results posted.
None of its findings points the other way.
- 2 independent labs in 1 country
- 2 trials, none about aging, 1 with no results posted
- Funder: National Natural Science Foundation of China
- Animals2
What did studies of psoralen find?
4Studies of psoralen measured 4 outcomes, among them Osteoblast proliferation, APP phosphorylation and bone degenerative lesions.
Osteoblast proliferation
upin mouse cells1
1 study
Osteoblast proliferation
upin mouse cells1
Psoralen increases osteoblast proliferation in mouse cells.
“intervention with psoralen in osteoblasts promoted osteoblast proliferation”
Cellsosteoblast
American journal of translational research
APP phosphorylation
downin mice1
1 study
APP phosphorylation
downin mice1
Psoralen inhibits APP phosphorylation in mice.
“Psoralen regulates bone degenerative diseases by inhibiting APP phosphorylation”
Animals
American journal of translational research
Bone degenerative lesions
downin mice1
1 study
Bone degenerative lesions
downin mice1
Psoralen decreases bone degenerative lesions in mice.
“Intervention with psoralen was effective for ameliorating the pathologic condition of bone degenerative lesions in mice”
Animalsin three degenerative models (knee osteoarthritis, osteoporosis, intervertebral disc degeneration)bone
American journal of translational research
cAMP signaling
upin mouse cells1
1 study
cAMP signaling
upin mouse cells1
Psoralen activates cAMP signaling in MEFs.
“Psr co-treatment potently activated the ADCY9/cAMP/PKA/CREB pathway”
Cellsin MEFs
Pharmaceutics
Has psoralen been tested in people?
0 of 2 about aging2 trials are registered, but no study of it in people has been published yet.
In trials
Phase 2Terminated2 trials
Phase 2Terminated2 trials
Phase 2Terminated2 trials
Phase 2Terminated1 trial
Phase 1Completed1 trial
Leukemia myeloid acute
Phase 1Completed1 trial
All 12Fewer
Stopped
NCT00676806TerminatedLeukemia
Slow accrual
Trial sponsors
1 trialPhase 27 people
1 trialPhase 17 people